Saturday 17 October 2026
Export LONA’s income statement to Excel — free account
LeonaBio, Inc.
LONA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.6% and free cash flow fell 142.3%, each against the same quarter a year earlier.
5.20
0.09
−1.70%
Follow LONA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 157.90 | 88.80 | 25.30 | 13.30 | 4.12 | 2.20 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 347.90 | 342.50 | 142.20 | 44.10 | 42.98 | 8.36 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 22 | 35 | 64 | 67 | 26 | 19 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (5) | (5) | (20) | (55) | (96) | (118) | (97) | (106) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (5) | (5) | (20) | (55) | (96) | (118) | (97) | (106) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (14.69) | (14.47) | (16.70) | (14.90) | (25.30) | (30.90) | (25.20) | (24.70) | |||||
| Cash flow | — | — | (12.92) | (10.41) | (20.15) | (11.67) | (19.21) | (26.50) | (25.25) | (10.69) | |||||
| Capex | — | — | 0.00 | 0.00 | (1.94) | (0.43) | (0.30) | (0.08) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | (12.92) | (10.41) | (22.09) | (12.10) | (19.51) | (26.58) | (25.26) | (10.69) | |||||
| Book value | — | — | 6.24 | (7.49) | 229.20 | 86.97 | 62.32 | 34.24 | 11.65 | 6.50 | |||||
| Shares, m | — | — | 0 | 0 | 1 | 4 | 4 | 4 | 4 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (4) | (4) | (24) | (43) | (72) | (101) | (97) | (46) | ||||
| Capex | — | — | — | — | (2) | (2) | (1) | 0 | 0 | — | |||||
| Free cash flow | — | — | (4) | (4) | (26) | (45) | (74) | (101) | (97) | (46) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 4 | 1 | 188 | 252 | 186 | 126 | 42 | 42 | ||||
| Total debt | — | — | 1 | 2 | 1 | 2 | 2 | — | — | — | |||||
| Net debt | — | — | (4) | (1) | (185) | (254) | (200) | (147) | (51) | (88) | |||||
| Shareholders’ equity | — | — | 2 | (3) | 274 | 321 | 235 | 130 | 45 | 28 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (206.65) | (144.93) | (14.16) | (17.94) | (32.41) | (56.25) | (88.52) | (139.94) | ||||
| ROIC | — | — | 0.00 | 0.00 | (13.95) | (59.43) | (186.85) | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 29.45 | 29.82 | (15.68) | (18.43) | (34.39) | (64.42) | (110.77) | (290.81) | |||||
Negative figures in brackets.
Charts ten years each
LeonaBio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INKT MiNK Therapeutics, Inc. | $50.7M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LONA LeonaBio, Inc. | $49.8M | — (loss-making) | — | — | n/m | −142.29% (below 0%: shrinking) | 0.00% | 0.00% | |
| CRBU Caribou Biosciences, Inc. | $49.8M | — (loss-making) | — (loss-making) | −43.79% (below 0%: shrinking) | n/m | −33.16% (below 0%: shrinking) | 100.00% | (1,690.39%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $49.3M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HYPD Hyperion DeFi, Inc. | $49.0M | — (loss-making) | 3.6× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $48.5M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| ELTX Elicio Therapeutics, Inc. | $48.2M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ACET Adicet Bio, Inc. | $48.1M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $47.8M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $48.7M | — | — | +256.11% | — | +16.47% | 0.00% | 0.00% |
LeonaBio, Inc. (LONA) key facts
- Concern: LeonaBio, Inc. reported a net loss of $105.6 million, or a loss of $24.70 per share, for fiscal 2025.
- LeonaBio, Inc. (LONA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, LONA traded at $5.20, a market capitalization of $49.8 million.
- Return on equity was −290.8% and debt-to-equity 0.00.